Nanoparticle Chelators for Tumor Copper and Iron Capture
Solution Overview
Problem
Current treatments for metastatic cancers using copper and iron chelators face challenges such as non-specific binding to essential metals, leading to side effects, limited targeting of tumors, and rapid elimination, which hampers effective and specific capture of copper and iron in tumor environments.
Innovation Solution
Development of nanoparticles with a specific chelating group formula [Ch1]n—PS—[Ch2]m, where PS is an organic or inorganic polymer matrix, Ch1 is a chelating group with high affinity for copper or iron, and Ch2 is complexed with a metal cation of high atomic number, optimized for size, ratio, and biodistribution to achieve targeted and sustained chelation within tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If simple chelating agents are used to reduce copper and iron content, then treatment efficacy is improved, but side effects increase due to non-specific binding to essential metals
Solution Approach 1:
The patent applies local quality by functionalizing nanoparticles with specific chelating groups that have high affinity for copper and iron, while the nanoparticle core provides targeting capability. This creates a localized treatment effect at the tumor site with [Ch1]n—PS—[Ch2]m formula, where Ch1 and Ch2 are specific chelating groups grafted to polymer matrix PS, ensuring that copper and iron depletion occurs preferentially in tumor tissue rather than systemically throughout the body.
Solution Approach 2:
The nanoparticle acts as an intermediary carrier that delivers chelating agents to the tumor site. The nanoparticle structure with grafted chelating groups serves as a mediator between the chelating function and the tumor target, enabling controlled release and localized action. This intermediary approach allows the chelating agents to function effectively while minimizing systemic exposure and associated side effects.
2Quantity of substance
If chelators with high affinity for copper and iron are used, then extraction capacity is improved, but specificity for other essential metals decreases leading to problematic side effects
Solution Approach 1:
The patent applies parameter changes by optimizing the chelating group structure and its binding parameters for copper and iron specificity. The chelating groups [Ch1] and [Ch2] are selected and designed with specific chemical properties that favor binding to copper and iron over other essential metals like zinc and manganese. This parameter optimization ensures high extraction capacity for target metals while maintaining specificity and avoiding depletion of other essential metals.
3Reliability
If nanoparticles with larger size are used for tumor targeting, then targeting capability is improved, but biodistribution leads to accumulation in liver, spleen, kidneys and lungs
Solution Approach 1:
The patent applies parameter changes by optimizing the nanoparticle size parameter to a specific range that balances targeting capability with favorable biodistribution. The nanoparticles are designed with controlled size and surface properties that enable tumor accumulation through enhanced permeability and retention effect while maintaining sufficient renal clearance. This size optimization prevents excessive accumulation in reticuloendothelial system organs while preserving tumor targeting efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticles enable efficient and specific capture of copper and iron in tumor environments, reducing side effects and enhancing the radiosensitizing effect during radiotherapy, thereby improving treatment efficacy while minimizing systemic impact.
Implementation Method 1
Ch1 is a chelating group which is uncomplexed or is complexed with a metal cation M1... Ch2 is a chelating group, identical to or different from the chelating group Ch1, and complexed with a metal cation M2
Data Source
AI summary
The present disclosure relates to nanoparticles and the uses thereof in medicine, in particular for the treatment of tumours.



